← Back to Search

Janus Kinase Inhibitor

Delgocitinib cream for Hair Loss

Phase 2

Waitlist Available

Research Sponsored by LEO Pharma

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and week 12

Summary

This trial is testing a skin cream called delgocitinib on people with frontal fibrosing alopecia (FFA), a type of hair loss. The cream aims to reduce skin inflammation and immune responses to help stop or reverse hair loss.

Eligible Conditions

Hair Loss

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and week 12

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and week 12

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in expression of chemokine (C-X-C motif) ligand 9 (CXCL9), chemokine (C-X-C motif) ligand 10 (CXCL10), and interferon (IFN)-γ from baseline to Week 12.

Side effects data

From 2022 Phase 3 trial • 487 Patients • NCT04871711

11%

COVID-19

Nasopharyngitis

Headache

Allergy to metals

Dermatitis contact

100%

80%

60%

40%

20%

Study treatment Arm

Delgocitinib |20 mg/g

Vehicle|

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Placebo Group

Group I: Delgocitinib - DelgocitinibExperimental Treatment1 Intervention

Participants will be blinded and randomised to delgocitinib cream treatment for the first 12 weeks, followed by an open label treatment with delgocitinib cream treatment for another 12 weeks.

Group II: No treatmentActive Control1 Intervention

Participants will not receive any treatment. They will only provide a molecular signature of healthy skin to act as a control.

Group III: Placebo - DelgocitinibPlacebo Group2 Interventions

Participants will be blinded and randomised to placebo cream treatment for the first 12 weeks, followed by an open label treatment with delgocitinib cream treatment for another 12 weeks.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Delgocitinib

Not yet FDA approved

Do I qualify?Apply below to find out